Drug Trial Radar · NCT07668518
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Aug 5, 2026
Primary completion
Mar 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Kither Biotech SrlIndustry
- Sponsor type
- Industry
- Collaborators
- Avance Clinical Pty Ltd.
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study investigating the safety, tolerability, pharmacokinetics and early efficacy with KIT2014 over 7 days of treatment in moderate to severe chronic obstructive pulmonary disease patients.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
KIT2014Drug
KIT2014 will be administered by inhalation with a nebuliser
PlaceboDrug
Placebo will be administered by inhalation with a nebuliser
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events(TEAEs),serious adverse events(SAEs)Time frame: From first dose to post-treatment follow up visit on Day 9.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Novatrials
Charlestown, New South Wales, Australia · Recruiting
Emeritus Research Sydney
Sydney, New South Wales, Australia · Not yet recruiting
Emeritus Research
Camberwell, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.